ClinicalTrials.gg
Not yet recruitingNCT07109284NeoSaciAUpdated Aug 7, 2025

SKB264 Combined With KL-A167 Neoadjuvant Therapy for Early-stage, High-risk ER+/HER2- Breast Cancer

A Phase 2 interventional study of Sacituzumab tirumotecan and Tagitanlimab in ER+HER2- Breast Cancer, sponsored by West China Hospital. Not yet recruiting. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by West China Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Breast Neoplasms by West China Hospital — 6 open to participants now, 6 under way, 1 of them phase 3. Breast Neoplasms · West China Hospital.

Started
2025
the only one that year
Phase 2
3 of 11
1 open now
Registered
6th of 11
by date

Among the 11 studies in Breast Neoplasms by West China Hospital, this one is the only one that started in 2025, is one of 3 in phase 2, and was the 6th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 11 studies in Breast Neoplasms by West China Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms by West China Hospital, or all of them as a file.
02

Study summary

This study aimed to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant therapy in early-stage high-risk ER+HER2- breast cancer patients.

Read the detailed description

This is a single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of SKB264 combined with KL-A167 as neoadjuvant treatment for early-stage high-risk ER+HER2- breast cancer. Eligible patients receive intravenous injections of 5mg/kg SKB264 and 900mg KL-167 every 2 weeks, with a total duration of 18 weeks for neoadjuvant therapy.

During neoadjuvant therapy, tumor assessments will be conducted every 6 weeks, followed by surgery after neoadjuvant therapy is completed. Following surgery, participants have the option to receive additional adjuvant therapy at the discretion of the treating physician. Participants will be followed at least every 6 months initially as per standard clinical practice.

The primary endpoint is to determine the pCR rate of SKB264 combined with KL-A167. Secondary endpoints include ORR, EFS, OS, and safety profile. Safety was evaluated by measuring the occurrence and severity of adverse effects by National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0.

03

Conditions studied

  • ER+HER2- Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 18-70 years;
  2. confirmed invasive ductal breast cancer and untreated previously;
  3. (ECOG) performance status of 0 to 1;
  4. ≥3 months;
  5. Have at least 1 defined by v1.1;
  6. T1c-T2 (tumor size ≥2 cm), clinical node stage (cN)1-cN2, or T3-T4, cN0-cN2;
  7. Has confirmed ER+/-:ER≥1%、HER2 IHC 0、1+ or 2+/ISH-);
  8. Tumor Grade 3 of ductal histology, Or Tumor Grade 2 of ductal histology having an ER expression level percentage between 1-10%
  9. Tissue or blood available for biomarker assessment;
  10. Adequate organ function;
  11. Patients with negative serum pregnancy test and those with fertility potential must agree to use effective during the treatment period and for at least 3 months after the last dose of study drugs;
  12. Patients must voluntarily participate in this study, sign an form, exhibit good compliance, and be willing to cooperate with follow-up procedures;

Exclusion criteria

Exclusion Criteria:

  1. Inflammatory BC;
  2. Has multi-centric breast cancer (presence of more than 1 tumor in different quadrants of the breast).
  3. Has bilateral invasive breast cancer.
  4. Has (stage IV) breast cancer.
  5. Has (LVEF) of \<50% or below the institution limit of normal, as assessed by echocardiogram (ECHO) or multigated acquisition (MUGA) scan performed at screening.
  6. Has received prior treatment for breast cancer.
  7. Has received prior therapy with an anti-programmed cell death protein 1 (), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137).
  8. Has received prior treatment for targeting TROP2 and/or topoisomerase I;
  9. Patients who have had other within the past five years will be excluded from the study, with exceptions for those who have been successfully treated for cervical carcinoma in situ, skin basal cell carcinoma, or squamous cell carcinoma of the skin;
  10. Has to any of the components or used in the study treatments.
  11. History of allogeneic organ transplantation;
  12. Patients with a history of non-infectious interstitial lung disease (ILD) or non-infectious pneumonia requiring treatment, those currently diagnosed with ILD or non-infectious pneumonia, or those with suspected ILD or non-infectious pneumonia that cannot be ruled out by imaging at the time of screening, will be excluded. Additionally, patients suffering from clinically severe pulmonary damage due to pulmonary comorbidities will also be excluded. This includes, but is not limited to, any underlying pulmonary disease (such as pulmonary embolism within the past three months, severe asthma, advanced , restrictive lung disease, pleural effusion) or any , connective tissue, or inflammatory conditions potentially affecting the lungs (such as rheumatoid arthritis, Sjögren's syndrome, sarcoidosis), as well as those who have undergone a pneumonectomy.
  13. Patients with active autoimmune diseases requiring systemic treatment within the past two years will be excluded from the study. Systemic treatment does not include hormone replacement therapy, such as insulin therapy for Type 1 Diabetes, thyroid hormone replacement for hypothyroidism, or physiological doses of glucocorticoids for adrenal or pituitary insufficiency.
  14. Patients with active infection requiring systemic therapy.
  15. According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study, including but not limited to high blood pressure beyond the control of drugs, serious diabetes, active infection, etc.
  16. Patients for whom participation in the study was deemed to be inappropriate by the investigator for any other reason were also excluded.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Experimental
    Sacituzumab Tirumotecan + Tagitanlimab

    Participants receive Sacituzumab Tirumotecan every 2 weeks (q2w) in combination with Tagitanlimab every 2 weeks (q2w) for 18 weeks. In addition, participants receive an antihistamine, an H2 antagonist of investigator's choice, acetaminophen (or equivalent), and dexamethasone (or equivalent) per each drug's product label prior to sacituzumab tirumotecan infusions.

    Biological: Sacituzumab tirumotecan · Biological: Tagitanlimab

Interventions

  • Sacituzumab tirumotecan 5 mg/kg, intravenously (iv), Q2W

    Also known as: SKB264, sac-TMT

  • BiologicalTagitanlimab

    Tagitanlimab 900mg, intravenously (iv), Q2W

    Also known as: KL-A167

06

What researchers measure

Primary outcomes

  1. Pathological Complete Response (pCR) Rate (ypT0/Tis ypN0)

    No microscopically detectable remnants of aggressive tumors in breast and axillary lymph nodes, ductal carcinoma in situ is allowed

    Time frame: Up to approximately 6 months (Time of surgery)

Secondary outcomes

  1. pCR Rate (ypT0/Tis)

    No microscopically detectable remnants of aggressive tumors in breast, ductal carcinoma in situ is allowed.

    Time frame: Up to approximately 6 months (Time of surgery)

  2. Objective response rate (ORR)

    The percentage of participants with CR or PR as the best response during the neoadjuvant treatment, based on RECIST v1.1.

    Time frame: Up to approximately 6 months (Time of surgery)

  3. Event-Free Survival (EFS)

    The time from the first treatment to disease progression that: precludes surgery, results in a local or distant recurrence, results in a second primary malignancy, or death due to any cause whichever occurs first.

    Time frame: Up to approximately 3 years

  4. Overall Survival (OS)

    The time from the date of first treatment to date of death due to any cause.

    Time frame: Up to approximately 3 years

  5. Adverse events (AEs)

    Evaluated by NCI CTCAE (version 5.0) : 1. The incidence, severity, and correlation with the investigational drug of adverse events (AE), treatment-related adverse events (TRAE), and serious adverse events (SAE); 2. The number and proportion of subjects who reduced their dosage and stopped treatment due to the aforementioned adverse events; 3. Study the changes in vital signs, physical examination results, and laboratory results before, during, and after treatment.

    Time frame: Up to approximately 9 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jan 2028, 28 months later.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 28 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 7, 2025
StartEst.
Sep 2025
Primary completionEst.
Jan 2028
CompletionEst.
Dec 2030
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109284
Responsible party
Shuangyue Liu (Professor, West China Hospital) — Principal investigator
First posted
Aug 7, 2025
Start date
Sep 2025 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Aug 7, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sacituzumab tirumotecan · Tagitanlimab

Start the discussion